AzTrials
AzTrials

TBI DepressionPhase 2/3rTMS TBINCT02367521

Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression & Other Neuropsychiatric Symptoms After Traumatic Brain Injury (TBI)

A Phase 2/3 study testing Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS) in people with TBI Depression, run by Johns Hopkins University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Traumatic brain injury (TBI) is frequently complicated by depression and other problems such as post traumatic stress disorder (PTSD), sleep disturbance, cognitive deficits and behavioral problems. Untreated depression can lead to reduced productivity and poor global outcome. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
TBI Depression
What is being tested?
Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
70 participants
Where
1 siteUnited States
Study dates
Mar 2015to 1 Oct 2017
Phase
Phase 2/3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults aged 18 and over
  • H/o closed head injury
  • Must meet Department of Defense (DoD) criteria for mild or moderate Traumatic Brain Injury (TBI)
  • Must meet criteria for major depression as assessed by the Structured Clinical Interview (SCID) for Diagnostic and Statistical Manual IV (DSM-IV) and a score greater than 10 on the Hamilton Depression 17 (HAM-D17) Scale

Who cannot join

  • Subjects with skull fracture
  • Subjects who meet DoD criteria for severe TBI
  • Subjects who are on psychotropics or mood stabilizing medications (e.g. antidepressants, antipsychotics, anxiolytics, sedative/hypnotics.
  • Subjects who are medically unstable
  • History of active substance abuse x 1 month
  • Current psychotic illness
Show all 20Show fewer
  • Evidence of frontal lesions on brain scan.
  • Individuals with a significant neurological disorders that could increase risk of seizures such as brain tumor, cerebral aneurysm, any h/o seizures and/or family h/o seizures
  • Dementia
  • Mini Mental State Exam score of less than or equal to 24
  • A positive and unmitigated response to any question on the Transcranial Magnetic Stimulation Safety Screen questionnaire
  • Electroconvulsive therapy (ECT) treatment within 6 months prior to the screening visit
  • History of treatment with rTMS therapy for any disorder
  • History of treatment with Vagus Nerve Stimulation (VNS)
  • History of treatment with Deep Brain Stimulation (DBS)
  • Cardiac pacemakers, implanted medication pumps, intracardiac lines,
  • Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed.
  • Implanted neurostimulators
  • Known or suspected pregnancy
  • Investigators, personnel affiliated with this study, and their immediate families.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Johns Hopkins Bayview Medical Center

    Baltimore, Maryland, 21224

Other trials in United States

About this study

Traumatic brain injury (TBI) is frequently complicated by depression and other problems such as post traumatic stress disorder (PTSD), sleep disturbance, cognitive deficits and behavioral problems. Untreated depression can lead to reduced productivity and poor global outcome. There is no Food and Drug Administration (FDA) approved drug for the treatment of TBI-related depression. The overarching goal of this small study is to determine the effectiveness of low frequency right (LFR) rTMS for the treatment of post-TBI depression and co-occurring psychiatric symptoms. Repetitive transcranial magnetic stimulation (rTMS) is a brain stimulation technique. It involves generating a brief magnetic field in a coil that is placed on the scalp. The magnetic field passes through the skull and induces a weak electrical current in the brain that briefly activates neural circuits at the stimulation site. Adults aged 18 and older, with a history of head injury of mild or moderate severity , who are currently experiencing symptoms of clinical depression may join the study.

Conditions
TBI Depression
Being tested
Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS), Sham Comparator: Sham Treatment
Keywords
TBI Depression, co-morbid psychiatric symptoms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)Combination product

    Also called low frequency right rTMS

    LFR rTMS will be delivered at the Brain Stimulation Program at The Johns Hopkins Hospital with a Magstim Super Rapid 2 stimulator with a focal double 70-mm air cooled coil. LFR rTMS will be administered to the Experimental Group.

    Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength.

  • Sham Comparator: Sham TreatmentDevice

    Also called Placebo

    Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength

Study groups in NCT02367521
Study groupRoleWhat they receive
LFR rTMSExperimentalInvestigators propose to deliver 1200 pulses daily at 110% Motor threshold for 4 weeks using four trains of 300 pulses daily separated by an intertrain interval of 60 seconds.
Receives: Combination Product: Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)
Sham TreatmentPlacebo comparatorControl patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
Receives: Device: Sham Comparator: Sham Treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Average Depression Score Using the Hamilton Depression (HAM-D) 17 Scale

    The HAM-D was used to determine the effectiveness of LFR rTMS for the treatment of post-TBI depression. The scale ranges from 0-54, with 0-7 = Normal; 8-13= Mild Depression; 14-18= Moderate Depression, 19-22= Severe Depression, >/= 23 = Very Severe Depression.

    Measured: Mean at baseline, 4 weeks, 8 weeks, 12 weeks, and 16 weeks

  2. Mean Clinical Global Improvement- Severity/Improvement Scale Score (CGI-I/CGI-S)

    The CGI scale is broken down into the CGI-S and CGI-I components. CGI-S is the baseline severity of mental illness. 1= normal, not at all ill; 2= borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. The CGI-S is only performed at baseline.

    The CGI-I component (which is any measure after intervention) is as follows: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment.

    Measured: Mean at baseline, 4, 8, 12, and 16 weeks

  3. Mean Suicidal Ideation as Assessed by the Beck Suicidal Ideation Scale (BSSI)

    The BSSI scale is used to assess the degree of suicidal ideation. The scale ranges from 0-38, with 0= no suicidality, and 38 = highest severity of suicidal ideation

    Measured: Mean at baseline, 4, 8, 12, and 16 weeks

Secondary outcomes (21)
  1. Ability to Inhibit Cognitive Interference as Assessed by the Stroop Color Word Test (SCWT)

    The SCWT is used to assess the ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute. Participants are required to read three different tables as fast as possible. Two of the tables represent the "congruous condition" in which participants are required to read names of colors printed in black ink and name different color patches. In the third table, "incongruous condition" the color-words are printed in a different color in (ie: the word "red" is printed in green ink). Within this third table, participants are required to name the color of the ink instead of reading the word. The score is based on the number of items completed, which ranges from 0 to 100, with a higher score reflecting a better outcome.

    Measured: Mean at baseline and 16 weeks

  2. Cognitive Reasoning as Assessed by the Number of Completed Categories on the Wisconsin Card Scoring Test (WCST)

    The participant points to choice on the screen and the tester manipulates the mouse to make the response. The participant tells the tester if he or she wants to change the response and the tester clicks on the screen. The score is the number of completed categories, ranging from 0-6. A higher score reflects a better outcome.

    Measured: Mean at baseline and 16 weeks

  3. Cognitive Reasoning as Assessed by the Number of Errors Made on the Wisconsin Card Sorting Test (WCST)

    The participant points to choice on the screen and the tester manipulates the mouse to make the response. The participant tells the tester if he or she wants to change the response and the tester clicks on the screen. The score is the number of errors, ranging from 0-128. A higher score reflects a poorer outcome.

    Measured: Mean at baseline and 16 weeks

  4. Cognitive Reasoning as Assessed by the Number of Correct Trials on the Wisconsin Card Scoring Test (WCST)

    The participant points to choice on the screen and the tester manipulates the mouse to make the response. The participant tells the tester if he or she wants to change the response and the tester clicks on the screen. The score is the number of correct trials, ranging from 0-128. A higher score reflects a better outcome.

    Measured: Mean at baseline and 16 weeks

  5. Evaluation of Brain Injury as Assessed by the Trailmaking Test B Score

    The Trailmaking B score is the number of seconds spent connecting numbered circles (1-13) to circles containing letters of the alphabet (A-L) in alternating sequential order. A maximum of 300 seconds is allowed. Score ranges from 0-300. Higher score reflects poorer outcome.

    Measured: Mean at baseline and 16 weeks

  6. Immediate Recall as Assessed by Hopkins Verbal Learning Test (HVLT)

    The Hopkins Verbal Learning Test (HVLT) consists of a 12-item word list, composed of four words from each of the three semantic categories. The subject is instructed to listen carefully as the examiner reads the word list and attempt to memorize the words. The word list is then read to the subject at the approximate rate of one word every 2 seconds. This is done for three trials. The number of correctly-recalled words in each trial is recorded (maximum of 12). The score is a sum of all the correctly-recalled words from each trial, for a maximum score of 36.

    Measured: Mean at baseline and 16 weeks

  7. Delayed Recall as Assessed by Hopkins Verbal Learning Test (HVLT)

    The HVLT consists of a 12-item word list, composed of four words from each of the three semantic categories. The subject is instructed to listen carefully as the examiner reads the word list and attempt to memorize the words. The word list is then read to the subject at the approximate rate of one word every 2 seconds. This is done for three trials. After the third learning trial, the patient is read 24 words and is asked to say "yes" after each word that appeared on the recall list (12 targets) and "no" after each word that did not (12 distractors). Half of the distractors are drawn from the same semantic categories as the targets (related distractors) and half are drawn from other categories (unrelated distractors). The number of correctly-recalled words in each trial is recorded (maximum of 12 per trial). The score is the sum of all the correctly-recalled words from each trial, for a maximum of 36. T-scores are reported (average T-score of 50 (ranges 40-60)

    Measured: Mean at baseline and 16 weeks

  8. Delayed Recall as Assessed by Brief Visual Memory Test (BVMT)

    BVMT is used to evaluate visuospatial memory abilities in neuropsychological populations. A visual display of six simple figures arranged in a 2 × 3 matrix on an 8 × 11 booklet is shown to participants for three consecutive 10-second trials. After each trial, participants are to draw as many designs as accurately as they can and in the correct location after a 25-minute delay filled with other distractor tasks. Scoring of the delayed recall is based on the accuracy of the drawings and the location of the figures. For each figure, one point is awarded to each satisfactory domain resulting in a maximum of 12-points per trial for a total score range of 0-36, with higher scores indicating a better outcome.

    Measured: Mean at baseline and 16 weeks

  9. Immediate Recall as Assessed by Brief Visual Memory Test (BVMT)

    BVMT is used to evaluate visuospatial memory abilities in neuropsychological populations. A visual display of six simple figures arranged in a 2 × 3 matrix on an 8 × 11 booklet is shown to participants for three consecutive 10-second trials. After each trial, participants are to draw as many designs as accurately as they can and in the correct location. Scoring of the immediate recall is based on the accuracy of the drawings and the location of the figures. For each figure, one point is awarded to each satisfactory domain resulting in a maximum of 12-points per trial, for a total score ranging from 0-36, with a higher score reflecting a better outcome.

    Measured: Mean at baseline and 16 weeks

  10. Evaluation of Brain Injury as Assessed by the Trailmaking Test A Score

    Trailmaking A is a psychological test with a score that is the number of seconds spent in connecting 25 numbered circles in sequential order. Score ranges from 0-150. Higher score reflects poorer outcome.

    Measured: Mean at baseline and 16 weeks

  11. Mean Generalized Anxiety Disorder (GAD) - 7 Questionnaire

    The GAD-7 questionnaire is used as a screening tool and severity measure for generalized anxiety disorder. The scale ranges from 0 - 21.

    0-4 = normal 5-9 = mild 10-14 = moderate >15 = severe

    Measured: Baseline, 4, 8, 12, and 16 weeks

  12. Mean Trauma Severity as Assessed by the Davidson Trauma Scale (DTS)

    The DTS is a 17-item self-reported measure that assesses the 17 Diagnostic and Statistical Manual IV (DSM-IV) symptoms of post-traumatic stress disorder (PTSD).

    Items are rated on 5-point frequency (0 = "not at all" to 4 = "every day") and severity scales (0 = "not at all distressing" to 4 = "extremely distressing").

    The DTS yields a frequency score (ranging from 0 to 68), severity score (ranging from 0 to 68), and total score (ranging from 0 to 136). The severity score will be used to assess this outcome.

    Measured: Baseline, 4, 8, 12, and 16 weeks

  13. Mean Level of Fatigue as Assessed by Patient Sleep Quality Index (PSQI)

    The PSQI score scale ranges from 0-21. 0 = very good sleep quality 21 = very bad sleep quality A total score of "5" or greater is indicative of poor sleep quality (reflecting a higher level of fatigue)

    Measured: Baseline, 4, 8, 12, and 16 weeks

  14. Mean Level of Fatigue as Assessed by the Epworth Sleepiness Scale (ESS)

    The ESS is used to determine the level of daytime sleepiness. It is a questionnaire composed of 8 questions. The participant answers each question on a scale of 0 to 3 (0=no sleepiness, 1= mild sleepiness, 2= moderate sleepiness, 3= severe sleepiness). The total score is the sum of all responses for a maximum score of 24. A higher score reflects increased sleepiness.

    Measured: Baseline, 4, 8, 12, and 16 weeks

  15. Mean Cognitive Function as Assessed by the Montreal Cognitive Assessment (MOCA)

    MOCA is designed to assess cognitive impairment and Alzheimer's Disease. It is composed of the following:

    Visuospatial and Executive Functioning: 5 points Animal Naming: 3 points Attention: 6 points Language: 3 points Abstraction: 2 points Delayed Recall (Short-term Memory): 5 points Orientation: 6 points Education Level: 1 point is added to the test-taker's score if he or she has 12 years or less of formal education.

    Score ranges 0-31, with ≥ 26 being normal cognitive function. The lower the score, the greater the level of cognitive impairment.

    Measured: Mean at baseline and 16 weeks

  16. Presence of Neuropsychiatric Symptoms as Assessed by Neurobehavioral Rating Scale (NBRS)

    The NBRS is a 28-item interview which includes a test of orientation and memory for recent events, questions regarding emotional state, post-concussional symptoms, focused attention, and concentration (performing serial sevens), explanation of proverbs, tasks of planning and mental flexibility, and delayed recall of three objects presented at the beginning of a session. Observations are also made regarding the patient's fatigability, visible signs of anxiety, disinhibition, agitation, hostility, difficulties in expressive and receptive communication, and disturbance of mood. The balance of the items are rated according to the patient's performance on brief tasks and quality of answers to interview questions. Each of the 28 items are scored on a scale of 0 (not severe) to 6 (extremely severe), for a maximum score of 168. A higher score reflects increased severity of neuropsychiatric symptoms.

    Measured: Mean at baseline, 4, 8, 12, and 16 weeks

  17. Presence of Post-concussive Symptoms as Assessed by the Rivermead Post-Concussion Questionnaire (RPQ)

    Participants are asked to rate the severity of 16 different symptoms over the past 24 hours, on a severity scale from 0 to 4 (0 = not experienced, 1 = no more of a problem, 2 = mild problem, 3 = moderate problem, 4 = severe problem). The 16 symptoms include: headaches, dizziness, nausea and/or vomiting, hyperacusis, sleep disturbance, fatigue, being irritable, feeling depressed, feeling frustrated, forgetfulness, poor concentration, taking longer to think, blurred vision, light sensitivity, double vision, restlessness. Score ranges from 0 to 64, with a higher score reflecting increased severity of post-concussive symptoms.

    Measured: Mean at baseline, 4, 8, 12, and 16 weeks

  18. Fatigue Severity as Assessed by the Fatigue Severity Scale (FSS)

    The FSS is a 9-item questionnaire which measures the severity of fatigue and how it interferes with certain activities. The items are scored on a 7-point scale with 1=strongly disagree and 7=strongly agree. The score ranges from 9 to a maximum of 63. A higher score reflects greater fatigue severity.

    Measured: Mean at baseline, 4, 8, 12, and 16 weeks

  19. Aggressive Behavior as Assessed by the Modified Overt Aggression Scale (MOAS)

    MOAS measures four types of aggressive behavior as witnessed in the past week. Each section consists of five items, with the first section regarding verbal aggression, the second section focusing on aggression against property, the third section measuring autoaggression, and the fourth section concerning physical aggression. Participants are asked to check each item that is true over the last week. Items are allocated 0, 1, 2, 3 or 4 point(s), and then all points for each selected item are summed. The maximum total for each section is 10 if all items are selected. Total score ranges from 0-40 with a higher score indicating more aggressive behavior.

    Measured: Mean at baseline, 4, 8, 12, and 16 weeks

  20. Overall Satisfaction With Life as Assessed by the Satisfaction With Life (SWL) Questionnaire

    The SWL is a 7-point Likert-style response scale. The possible range of scores is 5-35, with a score of 20 representing a neutral point on the scale. Scores between 5-9 indicate the respondent is extremely dissatisfied with life, whereas scores between 31-35 indicate the respondent is extremely satisfied.

    Measured: Mean at baseline, 4, 8, 12, and 16 weeks

  21. Presence of Social Connections as Assessed by the Social Ties Checklist (STC)

    The STC reflects the level of social contact. The score ranges from 0-10, with 0= excellent contact, 10=no contact. A higher score reflects poorer social contact.

    Measured: Mean at baseline, 4, 8, 12, and 16 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Feb 2015 (estimated)
  2. Study startMar 2015
  3. Primary completion1 Oct 2017
  4. Study completion1 Oct 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
70 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02367521
Sponsor's protocol ID
NA_00090926
Acronym
rTMS TBI
Status last verified
Aug 2018
First submitted
9 Feb 2015
Last updated
31 Aug 2018
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS) in people with TBI Depression, run by Johns Hopkins University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 31 Aug 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Average Depression Score Using the Hamilton Depression (HAM-D) 17 Scale (time frame: Mean at baseline, 4 weeks, 8 weeks, 12 weeks, and 16 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in